EB-102

**EB-102** is an investigational Eluminex Biosciences protein therapeutic candidate from the company's retinal-disease pipeline. Publicly available portfolio information associates the Eluminex EB-102 program with retinal diseases, and drug-database records identify diabetic retinopathy as a preclinical indication that was subsequently discontinued. The active ingredient, molecular target, pharmacologic mechanism, formulation, route of administration, and manufacturer have not been publicly disclosed. This record specifically concerns the discontinued Eluminex Biosciences program, not the separate preclinical EB-102 code reported for Elastin Bioscience.